Direct-acting antivirals (DAAs) target different steps of hepatitis C reproduction. These include hepatitis C protease inhibitors, polymerase inhibitors and NS5A inhibitors. Recommended regimens ...
Bemnifosbuvir is in Phase 2 development in combination with ruzasvir, an oral NS5A inhibitor, for the treatment of hepatitis c virus (HCV) infection. Bemnifosbuvir has a low risk of drug-drug ...